

**MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients**

Maria R. Ambrosio,<sup>1</sup> Stefano Lazzi,<sup>1</sup> Giuseppe Lo Bello,<sup>1</sup> Raffaella Santi,<sup>2</sup> Leonardo Del Porro,<sup>1</sup> Maria M. de Santi,<sup>3</sup> Raffaella Guazzo,<sup>1</sup> Lucia Mundo,<sup>1</sup> Luigi Rigacci,<sup>4</sup> Sofia Kovalchuck,<sup>4</sup> Noel Onyango,<sup>5</sup> Alberto Fabbri,<sup>6</sup> Emanuele Cencini,<sup>6</sup> Pier Luigi Zinzani,<sup>7</sup> Francesco Zaja,<sup>8</sup> Francesco Angrilli,<sup>9</sup> Caterina Stelitano,<sup>10</sup> Maria G. Cabras,<sup>11</sup> Giuseppe Spataro,<sup>12</sup> Roshanak Bob,<sup>13</sup> Thomas Menter,<sup>14,15</sup> Massimo Granai,<sup>1</sup> Gabriele Cevenini,<sup>1</sup> Kikkeri N. Naresh,<sup>15</sup> Harald Stein,<sup>13</sup> Elena Sabattini<sup>16</sup> and Lorenzo Leoncini<sup>1</sup>

<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Italy; <sup>2</sup>Division of Pathological Anatomy, University of Florence, Italy; <sup>3</sup>Unit of Pathological Anatomy, AOU Siena, Italy; <sup>4</sup>Hematology Division, AOU Careggi, University of Firenze, Italy; <sup>5</sup>Department of Clinical Medicine and Therapeutics, Unit of Medical Oncology, University of Nairobi, Kenya; <sup>6</sup>Haematology Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy; <sup>7</sup>Institute of Hematology "L. e A. Seragnoli", University of Bologna, Italy; <sup>8</sup>Clinica Ematologica ed Unità di Terapie Cellulari "Carlo Melzi", DAME, University of Udine, Italy; <sup>9</sup>Ematologia Ospedale Civile dello Spirito Santo, Pescara, Italy; <sup>10</sup>Ematologia, Ospedale Bianchi Melacrino Morelli, Reggio Calabria; <sup>11</sup>Hematology, Cagliari Hospital, Italy; <sup>12</sup>Post Graduate School of Public Health, University of Siena, Italy; <sup>13</sup>Pathodiagnostik Lab. Berlin, Germany; <sup>14</sup>Institute of Pathology and Medical Genetics, University Hospital of Basel, Switzerland; <sup>15</sup>Department of Cellular and Molecular Pathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS Trust, London, UK and <sup>16</sup>Unit of Haemolymphopathology, Department of Hematology and Oncology, University Hospital of Bologna, Italy

Correspondence: [lorenzo.leoncini@dbm.unisi.it](mailto:lorenzo.leoncini@dbm.unisi.it)

doi:10.3324/haematol.2018.195958

**Supplementary figure 1. Kaplan-Meier curves of progression free survival in the different groups of patients.**

**A: Kaplan-Meier curve of progression free survival in double hit (DH) *versus* double expressor (DE) *versus* non-double hit/non-double expressor (nonDH/nonDE) lymphomas.**

Progression free survival was significantly different between the DH and the other two groups (log rank test,  $p < 0.001$ ).

**B: Kaplan-Meier curve of progression free survival in double expressor (DE) depending on MYC protein expression.**

Progression free survival was significantly lower in the group showing MYC-IHC  $\geq 70\%$  than in the group with MYC-IHC 40-69% (log rank test,  $p = 0.001$ ).


**C: Kaplan-Meier curve of progression free survival in double hit (DH) depending on MYC protein expression.**

Progression free survival was significantly different among the two groups (MYC-IHC 0 to 69% and BCL-2-IHC  $\geq 50\%$ , and MYC-IHC  $\geq 70\%$  and BCL-2-IHC  $\geq 50\%$ ) with MYC  $\geq 70\%$  cases having the lower survival rate (log rank test,  $p < 0.001$ ). Noteworthy, among HGDH with MYC-IHC 0 to 69%, the 3 cases showing MYC-IHC  $< 40\%$  had a mean PFS of 42 months (data not shown).


**D: Kaplan-Meier curve of progression free survival in double hit (DH) *versus* double expressor (DE) as defined by MYC-IHC  $\geq 70\%$  and BCL-2-IHC  $\geq 50\%$  *versus* non-double hit/non-double expressor (nonDH/nonDE).**

Progression free survival overlaps in DH and DE with MYC-IHC  $\geq 70\%$  and BCL-2-IHC  $\geq 50\%$  (log rank test,  $p = 0.064$  for DH *versus* DE with MYC  $\geq 70\%$  and BCL-2-IHC  $\geq 50\%$ ;), being worse than the OS of the nonDH/nonDE (log rank test,  $p = 0.003$ ).


**PROGRESSION FREE SURVIVAL IN DOUBLE HIT versus DOUBLE EXPRESSOR versus NON DOUBLE HIT NON DOUBLE EXPRESSOR** A



**PROGRESSION FREE SURVIVAL IN DOUBLE EXPRESSOR DEPENDING ON MYC PROTEIN EXPRESSION** B



**PROGRESSION FREE SURVIVAL IN DOUBLE HIT DEPENDING ON MYC PROTEIN EXPRESSION** C



**PROGRESSION FREE SURVIVAL IN DOUBLE HIT versus DOUBLE EXPRESSOR with MYC 70-100% versus NON DOUBLE HIT NON DOUBLE EXPRESSOR** D

